Orphazyme Stock Analysis

ORPH -  USA Stock  

USD 1.98  0.02  1.00%

The big decline in price over the last few months for Orphazyme AS ADRmay encourage stockholders to take a closer look at the company as it is trading at a share price of 1.98 on 279,500 in trading volume. The company directors and management failed to add value to investors and positioning the company supply of money to exploit market volatility in December. However, diversifying your holdings with Orphazyme AS ADR or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.04. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Orphazyme partners.
Please check Your Equity Center.

Orphazyme Stock Analysis 

The Orphazyme stock analysis report makes it easy to digest most publicly released information about Orphazyme and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Orphazyme Stock analysis module also helps to analyze the Orphazyme price relationship with some important fundamental indicators such as market cap and management efficiency.

Orphazyme Stock Analysis Notes

The company has price-to-book ratio of 0.43. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Orphazyme AS ADR recorded a loss per share of 3.88. The entity had not issued any dividends in recent years. Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on NASDAQ Exchange in the United States. To find out more about Orphazyme AS ADR contact the company at 45 39 17 82 72 or learn more at https://www.orphazyme.com.

Orphazyme AS ADR Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Orphazyme's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Orphazyme AS ADR or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Orphazyme AS ADR generated a negative expected return over the last 90 days
Orphazyme AS ADR may become a speculative penny stock
Orphazyme AS ADR has high historical volatility and very poor performance
Orphazyme AS ADR has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 13.15 M. Net Loss for the year was (845.61 M).
Orphazyme AS ADR currently holds about 334.18 M in cash with (716.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.56, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from www.investorsobserver.com: Orphazyme AS Down 4.83 percent in Premarket Trading - InvestorsObserver

Orphazyme Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 74.45 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Orphazyme's market, we take the total number of its shares issued and multiply it by Orphazyme's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (88.16) % which means that it has lost $88.16 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (251.34) %, meaning that it created substantial loss on money invested by shareholders. Orphazyme management efficiency ratios could be used to measure how well orphazyme as adr manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 26th of January, Orphazyme holds the coefficient of variation of (384.08), and Risk Adjusted Performance of (0.21). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Orphazyme, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Orphazyme AS ADR, which can be compared to its competitors. Please check Orphazyme AS ADR variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Orphazyme AS ADR is priced some-what accurately, providing market reflects its current price of 1.98 per share. Please also confirm Orphazyme AS ADR total risk alpha, which is currently at (0.74) to check out the company can sustain itself at a future point.

Orphazyme AS ADR Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Simple Moving Average indicator is calculated by adding the closing price of Orphazyme for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Orphazyme AS ADR short-term fluctuations and highlight longer-term trends or cycles. View also all equity analysis or get more info about simple moving average overlap studies indicator.

Orphazyme Predictive Daily Indicators

Orphazyme intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Orphazyme stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Orphazyme Forecast Models

Orphazyme time-series forecasting models is one of many Orphazyme's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Orphazyme's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Orphazyme Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Orphazyme stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Orphazyme shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Orphazyme. By using and applying Orphazyme Stock analysis, traders can create a robust methodology for identifying Orphazyme entry and exit points for their positions.
Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on NASDAQ Exchange in the United States.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Orphazyme to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Holdings Now


Portfolio Holdings

Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
All  Next Launch Module
Please check Your Equity Center. Note that the Orphazyme AS ADR information on this page should be used as a complementary analysis to other Orphazyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Orphazyme Stock analysis

When running Orphazyme AS ADR price analysis, check to measure Orphazyme's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orphazyme is operating at the current time. Most of Orphazyme's value examination focuses on studying past and present price action to predict the probability of Orphazyme's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Orphazyme's price. Additionally, you may evaluate how the addition of Orphazyme to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Global Correlations
Find global opportunities by holding instruments from different markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Bond Directory
Find actively traded corporate debentures issued by US companies
Is Orphazyme's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orphazyme. If investors know Orphazyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orphazyme listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Orphazyme AS ADR is measured differently than its book value, which is the value of Orphazyme that is recorded on the company's balance sheet. Investors also form their own opinion of Orphazyme's value that differs from its market value or its book value, called intrinsic value, which is Orphazyme's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orphazyme's market value can be influenced by many factors that don't directly affect Orphazyme's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orphazyme's value and its price as these two are different measures arrived at by different means. Investors typically determine Orphazyme value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orphazyme's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.